Alnylam Pharmaceuticals Inc. (ALNY) said Thursday that it has separately filed suit in United States District Court for the District of Delaware against Pfizer Inc. and Moderna, Inc., seeking damages for infringement of U.S. Patent No. 11,246,933 in the parties' manufacture and sale of their mRNA COVID-19 vaccines.
The patent relates to Alnylam's biodegradable cationic lipids that are foundational to the success of the mRNA COVID-19 vaccines.
Alnylam said it does not plan to seek an injunction or take action that impedes production, sale or distribution of the vaccines.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.